Andere talen Immunovia AB

Aandelen

IMMNOV

SE0006091997

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:30 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,055 ^SEK	+2,75%		+17,16%	+15,97%

22/04	Immunovia AB kondigt positieve resultaten aan van de modelontwikkelingsstudie voor haar nieuwe generatie pancreaskankerdetectietest	CI
09/04	Immunovia, Proteomedix creëren assays voor alvleesklierkankerdetectietest	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Invitation to Immunovia's Q1 presentation	23/04
Immunovia announces updated financial calendar	22/04
Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test	22/04
Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test	22/04
Immunovia, Proteomedix Create Assays for Pancreatic Cancer Detection Test	09/04
Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study	09/04
Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study	09/04
Immunovia announces updated financial calendar	12/03
Immunovia Publishes Full Year Report for 2023	21/02
Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/02
Immunovia AB Reports Earnings Results for the Full Year Ended December 31, 2023	21/02
Invitation to Immunovia's Q4 presentation	14/02
Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs	31/01
Immunovia announces financial calendar for financial year 2024	04/01
Immunovia AB Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members	21/11
Bulletin from the extraordinary general meeting in Immunovia AB	21/11
Immunovia Publishes Interim Report for January-September 2023	09/11
Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Immunovia Shares Surge on Discovery Study for New Pancreatic Cancer Test	07/11
Immunovia successfully completes discovery phase of next-generation test development	07/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Immunovia AB

Aandelen

IMMNOV

SE0006091997

Andere talen

Filters